|Audentes Therapeutics Inc., of San Francisco, a unit of Astellas Pharma Inc.||AT-132||AAV8-delivered gene therapy||X-linked myotubular myopathy||Third of 17 patients treated at the same dose level died; preliminary finding for death is gastrointestinal bleeding; patient was 1 of 3 patients previously disclosed as having liver dysfunction within 3-4 weeks after dosing|
|Biontech SE, of Mainz, Germany, and Pfizer Inc., of New York||BNT-162b2||mRNA vaccine expressing spike glycoprotein of SARS-CoV2||COVID-19 prophylaxis||In patients 18-55 years of age, SARS-CoV-2-neutralizing geometric mean titers (GMT) 7 days after the second dose were 3.8 times the GMT seen in sera of SARS-CoV2 convalescent patients; in patients 65-85 years of age, GMT was 1.6 times level of convalescent patients|
|Sab Biotherapeutics, of Sioux Falls, S.D.||SAB-185||Neutralizing polyclonal antibody||Mild to moderate COVID-19||First of 21 patients treated in study testing the safety and pharmacological activity of SAB-185|
|Vaccibody AS, of Olso, Norway, and Nektar Therapeutics Inc., of San Francisco||VB10.NEO + bempegaldesleukin||Neoantigen cancer vaccine + CD122-preferential IL-2 pathway agonist||Advanced squamous cell carcinoma of the head and neck||First patient dosed in the study|
For more information about individual companies and/or products, see Cortellis.